Rigel Pharmaceuticals Inc vs Orsted A/S
A head-to-head of Rigel Pharmaceuticals Inc (RIGL) and Orsted A/S (DOGEF) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | RIGL | DOGEF |
|---|---|---|
| Market Cap | $564.75M | $537.44B |
| P/E (TTM) | 1.50 | 126.35 |
| Forward P/E | 6.45 | 0.66 |
| P/S | 1.92 | 7.34 |
| P/B | 1.41 | 2.00 |
| EV/EBITDA | 3.51 | 15.58 |
| Dividend Yield | — | — |
| Profit Margin | 124.72% | 2.97% |
| Gross Margin | 93.33% | -2.70% |
| Operating Margin | 42.63% | -2.70% |
| Revenue Growth (YoY) | +21.19% | +12.75% |
| FCF Yield | 13.40% | -5.87% |
| Debt / Equity | 13.51 | 83.48 |
| Current Ratio | 2.42 | 1.94 |
Which is better: Rigel Pharmaceuticals Inc or Orsted A/S?
- ✓Larger by market cap: Orsted A/S
- ✓Cheaper valuation (lower P/E): Rigel Pharmaceuticals Inc
- ✓More profitable (net margin): Rigel Pharmaceuticals Inc
- ✓Faster revenue growth: Rigel Pharmaceuticals Inc
- ✓Higher free-cash-flow yield: Rigel Pharmaceuticals Inc
Across 12 available metrics, Rigel Pharmaceuticals Inc leads 11–1.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Rigel Pharmaceuticals Inc with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.